Cargando…
Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment
BACKGROUND: Neoadjuvant (chemo) radiotherapy is used as a standard treatment for locally advanced rectal cancer (LARC), but there is no general consensus on either the efficacy of postoperative adjuvant chemotherapy in patients with LARC after neoadjuvant treatment and surgery, or whether the additi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319733/ https://www.ncbi.nlm.nih.gov/pubmed/34337057 http://dx.doi.org/10.1155/2021/8852699 |
_version_ | 1783730513854332928 |
---|---|
author | Li, Jia-yi Huang, Xuan-zhang Gao, Peng Chen, Xiao-wan Song, Yong-xi Lv, Xing-er Fu, Yv Xiao, Qiong Wang, Zhen-ning |
author_facet | Li, Jia-yi Huang, Xuan-zhang Gao, Peng Chen, Xiao-wan Song, Yong-xi Lv, Xing-er Fu, Yv Xiao, Qiong Wang, Zhen-ning |
author_sort | Li, Jia-yi |
collection | PubMed |
description | BACKGROUND: Neoadjuvant (chemo) radiotherapy is used as a standard treatment for locally advanced rectal cancer (LARC), but there is no general consensus on either the efficacy of postoperative adjuvant chemotherapy in patients with LARC after neoadjuvant treatment and surgery, or whether the addition of oxaliplatin to adjuvant chemotherapy provides survival benefits. METHODS: We performed a meta-analysis of data from the PubMed and Embase databases. We included patients with LARC who received neoadjuvant (chemo) radiotherapy and curative surgery. Overall survival (OS), disease-free survival (DFS), toxicity, and compliance were analyzed in the oxaliplatin/fluorouracil- (OX/FU-) based group compared with the FU-based group, and in the chemotherapy group compared with the observation group. RESULTS: Twenty studies were included in the analysis. Our results indicated that adjuvant chemotherapy prolonged OS (hazard ratio [HR] = 0.78, 95%CI = 0.67–0.91) in patients with LARC treated with neoadjuvant (chemo) radiotherapy and surgery compared with those in the observation group. Subgroup analysis showed the same results in both the ypStage II and ypStage III groups. Compared with those in the observation group, patients in the chemotherapy group also showed an increase in DFS (HR = 0.75, 95%CI = 0.60–0.93). No significant increase was observed in OS (HR = 1.04, 95%CI = 0.87–1.24) or DFS (HR = 0.98, 95%CI = 0.76–1.27) when oxaliplatin was added to FU-based adjuvant chemotherapy, as compared with the FU-based treatment, and subgroup analysis also indicated no survival benefits in the clinical stage II, clinical stage III, ypStage II, and ypStage III groups. CONCLUSIONS: For patients with LARC who have already received neoadjuvant (chemo) radiotherapy and curative surgery, adjuvant chemotherapy improves OS over that in the observation group. Adding oxaliplatin to FU-based adjuvant chemotherapy does not confer survival benefits beyond those from FU-based adjuvant chemotherapy. |
format | Online Article Text |
id | pubmed-8319733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-83197332021-07-31 Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment Li, Jia-yi Huang, Xuan-zhang Gao, Peng Chen, Xiao-wan Song, Yong-xi Lv, Xing-er Fu, Yv Xiao, Qiong Wang, Zhen-ning Biomed Res Int Research Article BACKGROUND: Neoadjuvant (chemo) radiotherapy is used as a standard treatment for locally advanced rectal cancer (LARC), but there is no general consensus on either the efficacy of postoperative adjuvant chemotherapy in patients with LARC after neoadjuvant treatment and surgery, or whether the addition of oxaliplatin to adjuvant chemotherapy provides survival benefits. METHODS: We performed a meta-analysis of data from the PubMed and Embase databases. We included patients with LARC who received neoadjuvant (chemo) radiotherapy and curative surgery. Overall survival (OS), disease-free survival (DFS), toxicity, and compliance were analyzed in the oxaliplatin/fluorouracil- (OX/FU-) based group compared with the FU-based group, and in the chemotherapy group compared with the observation group. RESULTS: Twenty studies were included in the analysis. Our results indicated that adjuvant chemotherapy prolonged OS (hazard ratio [HR] = 0.78, 95%CI = 0.67–0.91) in patients with LARC treated with neoadjuvant (chemo) radiotherapy and surgery compared with those in the observation group. Subgroup analysis showed the same results in both the ypStage II and ypStage III groups. Compared with those in the observation group, patients in the chemotherapy group also showed an increase in DFS (HR = 0.75, 95%CI = 0.60–0.93). No significant increase was observed in OS (HR = 1.04, 95%CI = 0.87–1.24) or DFS (HR = 0.98, 95%CI = 0.76–1.27) when oxaliplatin was added to FU-based adjuvant chemotherapy, as compared with the FU-based treatment, and subgroup analysis also indicated no survival benefits in the clinical stage II, clinical stage III, ypStage II, and ypStage III groups. CONCLUSIONS: For patients with LARC who have already received neoadjuvant (chemo) radiotherapy and curative surgery, adjuvant chemotherapy improves OS over that in the observation group. Adding oxaliplatin to FU-based adjuvant chemotherapy does not confer survival benefits beyond those from FU-based adjuvant chemotherapy. Hindawi 2021-03-28 /pmc/articles/PMC8319733/ /pubmed/34337057 http://dx.doi.org/10.1155/2021/8852699 Text en Copyright © 2021 Jia-yi Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Li, Jia-yi Huang, Xuan-zhang Gao, Peng Chen, Xiao-wan Song, Yong-xi Lv, Xing-er Fu, Yv Xiao, Qiong Wang, Zhen-ning Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment |
title | Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment |
title_full | Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment |
title_fullStr | Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment |
title_full_unstemmed | Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment |
title_short | Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment |
title_sort | postoperative adjuvant treatment strategy for locally advanced rectal cancer after neoadjuvant treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319733/ https://www.ncbi.nlm.nih.gov/pubmed/34337057 http://dx.doi.org/10.1155/2021/8852699 |
work_keys_str_mv | AT lijiayi postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment AT huangxuanzhang postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment AT gaopeng postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment AT chenxiaowan postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment AT songyongxi postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment AT lvxinger postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment AT fuyv postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment AT xiaoqiong postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment AT wangzhenning postoperativeadjuvanttreatmentstrategyforlocallyadvancedrectalcancerafterneoadjuvanttreatment |